¥2,601-35.00 (-1.33%)
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally.
Daiichi Sankyo Company, Limited in the Healthcare sector is trading at ¥2,601 with a market capitalization of $5.1T. Wall Street consensus targets ¥4,065 (16 analysts), implying a +56.3% move over the next 12 months. The stock is currently near its 52-week low of ¥2,390, remaining 6.5% below its 200-day moving average. Risk note: RSI 23 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (JPY) · Annual | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Total Revenue | ¥1.28T↓ | ¥1.60T↓ | ¥1.89T↓ | ¥2.12T |
| Gross Profit | ¥914.95B↓ | ¥1.19T↓ | ¥1.47T↑ | ¥1.45T |
| Operating Income | ¥120.58B↓ | ¥211.59B↓ | ¥331.93B↑ | ¥229.09B |
| Net Income | ¥109.19B↓ | ¥200.73B↓ | ¥295.76B↑ | ¥259.87B |
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adeno...